PIK3CA and salivary duct carcinoma: Individuals with salivary duct carcinoma can have phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations, which would sensitize the tumor to the mTOR inhibitor temsirolimus.